India's Medicamen Biotech rises after deal with Denmark's XGX Pharma

Medicamen Biotech

08/04/2025 09:19

** Medicamen Biotech MEBI.NS soars as much as 11.5% amid a broader market rebound; stock had dropped 8.4% on Monday, tracking a sell-off triggered by U.S. tariffs

** Gains helped by co's agreement with Denmark's XGX Pharma to distribute three products in Europe

** Co will hold marketing authorization of products

** More than 84,000 shares traded vs 30-day avg of 67,923

** MEBI last up 8.7%, cutting YTD losses to 10.6%

 (Reporting by Meenakshi Maidas in Bengaluru)

 ((meenakshi.maidas@thomsonreuters.com;))